search
Back to results

Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)

Primary Purpose

Infertility, Female

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
G-CSF
Saline
Sponsored by
Center for Human Reproduction
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility, Female focused on measuring Fertility Agents, Female, In vitro fertilization

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Women already enrolled in an IVF cycle at one of the participating institutions

Exclusion Criteria:

  • Sickle Cell disease
  • Renal insufficiency
  • Upper respiratory infection or Pneumonia
  • Chronic Neutropenia
  • Known Past or present malignancy

Sites / Locations

  • Center for Human Reproduction

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

G-CSF then Saline

Saline then G-CSF

Arm Description

G-CSF (Granulocyte colony stimulating factor)

Normal Saline

Outcomes

Primary Outcome Measures

Embryo Implantation and Clinical Pregnancy Rates
Implantation rate: The number of gestational sacs noted in the endometrial cavity 26 to 30 days after embryo transfer divided by the number of embryos transferred Clinical pregnancy: Gestational sac with evidence of a viable pregnancy at least 28 days after embryo transfer

Secondary Outcome Measures

Live Birth Rates
Live birth rates among normal infertile couples undergoing IVF

Full Information

First Posted
September 14, 2010
Last Updated
November 24, 2014
Sponsor
Center for Human Reproduction
Collaborators
Foundation for Reproductive Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT01202656
Brief Title
Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)
Official Title
G-CSF(Granulocyte Colony Stimulating Factor) and Embryo Implantation and Pregnancy Following IVF (in Vitro Fertilization)
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
June 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Center for Human Reproduction
Collaborators
Foundation for Reproductive Medicine

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This a trial designed to test whether granulocyte colony stimulating factor (G-CSF, Neupogen) can increase the rate of embryo implantation following IVF and embryo transfer. Preliminary data at the Center for Human Reproduction(CHR) and elsewhere suggest that intrauterine infusion of G-CSF can improve endometrial development and can increase implantation rates of embryos.
Detailed Description
Objective: To investigate the effect of treatment with CSF on pregnancy rates in routine in vitro fertilization (IVF). Design: Double blinded crossover randomized controlled clinical trial Setting: Academically affiliated private infertility centers Subjects: Normal female IVF patients 18-38 years old, and above age 38 years, who are willing to be randomized to treatment. Interventions: Subjects receive transvaginally, utilizing an insemination catheter, a slow uterine lavage with G-CSF (Neupogen), 300ug (in 1 ml); controls receive saline. Patients who do not conceive will, after one month washout time, continue treatment in the opposite study arm. Main Outcome Measures: Implantation rate(IR) and pregnancy rates. Second Outcome Measures: Live birth rates and miscarriage rates. Statistical and Power considerations: Analysis will be by regression with IR as dependent and treatment as independent. Results will be adjusted by age and indices of ovarian reserve, such as antiMulerian Hormone (AMH). Presuming an implantation rate of 10% and anticipating a 10% increase to 20% with treatment, 120 women, producing about 200 embryos in each study arm, will have to be recruited for 80% power and alpha of 0.05.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility, Female
Keywords
Fertility Agents, Female, In vitro fertilization

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
129 (Actual)

8. Arms, Groups, and Interventions

Arm Title
G-CSF then Saline
Arm Type
Experimental
Arm Description
G-CSF (Granulocyte colony stimulating factor)
Arm Title
Saline then G-CSF
Arm Type
Placebo Comparator
Arm Description
Normal Saline
Intervention Type
Drug
Intervention Name(s)
G-CSF
Other Intervention Name(s)
Neupogen (Filgrastim)
Intervention Description
One infusion of G-CSF 300 units administered by intrauterine infusion
Intervention Type
Drug
Intervention Name(s)
Saline
Other Intervention Name(s)
Normal Saline, 0.91% w/v of NaCl, about 300 mOsm/L
Intervention Description
intrauterine saline infusion 1 cc
Primary Outcome Measure Information:
Title
Embryo Implantation and Clinical Pregnancy Rates
Description
Implantation rate: The number of gestational sacs noted in the endometrial cavity 26 to 30 days after embryo transfer divided by the number of embryos transferred Clinical pregnancy: Gestational sac with evidence of a viable pregnancy at least 28 days after embryo transfer
Time Frame
26 to 30 days after embryo transfer
Secondary Outcome Measure Information:
Title
Live Birth Rates
Description
Live birth rates among normal infertile couples undergoing IVF
Time Frame
Within nine months of embryo transfer

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women already enrolled in an IVF cycle at one of the participating institutions Exclusion Criteria: Sickle Cell disease Renal insufficiency Upper respiratory infection or Pneumonia Chronic Neutropenia Known Past or present malignancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David H Barad, MD, MS
Organizational Affiliation
Center for Human Reproduction
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Norbert Gleicher, MD
Organizational Affiliation
Center for Human Reproduction
Official's Role
Study Chair
Facility Information:
Facility Name
Center for Human Reproduction
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
24424357
Citation
Barad DH, Yu Y, Kushnir VA, Shohat-Tal A, Lazzaroni E, Lee HJ, Gleicher N. A randomized clinical trial of endometrial perfusion with granulocyte colony-stimulating factor in in vitro fertilization cycles: impact on endometrial thickness and clinical pregnancy rates. Fertil Steril. 2014 Mar;101(3):710-5. doi: 10.1016/j.fertnstert.2013.12.016. Epub 2014 Jan 11.
Results Reference
result

Learn more about this trial

Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)

We'll reach out to this number within 24 hrs